174 related articles for article (PubMed ID: 29616857)
1. Pilot trial of K562/GM-CSF whole-cell vaccination in MDS patients.
Robinson TM; Prince GT; Thoburn C; Warlick E; Ferguson A; Kasamon YL; Borrello IM; Hess A; Smith BD
Leuk Lymphoma; 2018 Dec; 59(12):2801-2811. PubMed ID: 29616857
[TBL] [Abstract][Full Text] [Related]
2. Vaccines: a promising therapy for myelodysplastic syndrome.
Gera K; Chauhan A; Castillo P; Rahman M; Mathavan A; Mathavan A; Oganda-Rivas E; Elliott L; Wingard JR; Sayour EJ
J Hematol Oncol; 2024 Jan; 17(1):4. PubMed ID: 38191498
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
Liu Y; Bewersdorf JP; Stahl M; Zeidan AM
Blood Rev; 2019 Mar; 34():67-83. PubMed ID: 30553527
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy.
Kerkhoff N; Bontkes HJ; Westers TM; de Gruijl TD; Kordasti S; van de Loosdrecht AA
Immunotherapy; 2013 Jun; 5(6):621-37. PubMed ID: 23725285
[TBL] [Abstract][Full Text] [Related]
5. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer.
Nemunaitis J; Jahan T; Ross H; Sterman D; Richards D; Fox B; Jablons D; Aimi J; Lin A; Hege K
Cancer Gene Ther; 2006 Jun; 13(6):555-62. PubMed ID: 16410826
[TBL] [Abstract][Full Text] [Related]
6. WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides.
Brayer J; Lancet JE; Powers J; List A; Balducci L; Komrokji R; Pinilla-Ibarz J
Am J Hematol; 2015 Jul; 90(7):602-7. PubMed ID: 25802083
[TBL] [Abstract][Full Text] [Related]
7. Leukaemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with myelodysplasia: a methodological approach under serum-free culture conditions.
Kufner S; Zitzelsberger H; Kroell T; Pelka-Fleischer R; Salem A; de Valle F; Schmid C; Schweiger C; Kolb HJ; Schmetzer HM
Scand J Immunol; 2005 Jul; 62(1):75-85. PubMed ID: 16091127
[TBL] [Abstract][Full Text] [Related]
8. Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy.
Oka Y; Tsuboi A; Nakata J; Nishida S; Hosen N; Kumanogoh A; Oji Y; Sugiyama H
Oncol Res Treat; 2017; 40(11):682-690. PubMed ID: 29041012
[TBL] [Abstract][Full Text] [Related]
9. Serum-free generation and quantification of functionally active Leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes.
Kufner S; Fleischer RP; Kroell T; Schmid C; Zitzelsberger H; Salih H; de Valle F; Treder W; Schmetzer HM
Cancer Immunol Immunother; 2005 Oct; 54(10):953-70. PubMed ID: 15789235
[TBL] [Abstract][Full Text] [Related]
10. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
11. Monocyte derived dendritic cells have reduced expression of co-stimulatory molecules but are able to stimulate autologous T-cells in patients with MDS.
Davison GM; Novitzky N; Abdulla R
Hematol Oncol Stem Cell Ther; 2013 Jun; 6(2):49-57. PubMed ID: 23714180
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods.
Kremser A; Dressig J; Grabrucker C; Liepert A; Kroell T; Scholl N; Schmid C; Tischer J; Kufner S; Salih H; Kolb HJ; Schmetzer H
J Immunother; 2010; 33(2):185-99. PubMed ID: 20139775
[TBL] [Abstract][Full Text] [Related]
13. Retuning the immune system in myelodysplastic syndromes: from immunomodulatory approaches to vaccination strategies and non myeloablative hemopoietic cell transplant.
Fozza C
Crit Rev Oncol Hematol; 2019 Jan; 133():112-119. PubMed ID: 30661647
[TBL] [Abstract][Full Text] [Related]
14. Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes.
Ivy KS; Brent Ferrell P
Curr Hematol Malig Rep; 2018 Aug; 13(4):244-255. PubMed ID: 29934935
[TBL] [Abstract][Full Text] [Related]
15. SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Activates CD4
Lacher MD; Bauer G; Fury B; Graeve S; Fledderman EL; Petrie TD; Coleal-Bergum DP; Hackett T; Perotti NH; Kong YY; Kwok WW; Wagner JP; Wiseman CL; Williams WV
Front Immunol; 2018; 9():776. PubMed ID: 29867922
[TBL] [Abstract][Full Text] [Related]
16. The use of haemopoietic growth factors in the treatment of myelodysplastic syndromes.
Greenberg PL; Negrin R; Nagler A
Cancer Surv; 1990; 9(1):199-212. PubMed ID: 2276114
[TBL] [Abstract][Full Text] [Related]
17. Immunobiologic therapies for myelodysplastic syndrome.
Appelbaum FR
Best Pract Res Clin Haematol; 2004 Dec; 17(4):653-61. PubMed ID: 15494301
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic transplantation for myelodysplastic syndrome (MDS).
Ingram W; Lim ZY; Mufti GJ
Blood Rev; 2007 Mar; 21(2):61-71. PubMed ID: 16759774
[TBL] [Abstract][Full Text] [Related]
19. Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy.
Aggarwal S; van de Loosdrecht AA; Alhan C; Ossenkoppele GJ; Westers TM; Bontkes HJ
Br J Haematol; 2011 Jun; 153(5):568-81. PubMed ID: 21488861
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease-directed immunotherapy for high-risk myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Mo X; Zhang X; Xu L; Wang Y; Yan C; Chen H; Chen Y; Han W; Wang F; Wang J; Liu K; Huang X
Front Med; 2019 Jun; 13(3):354-364. PubMed ID: 30680605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
